CAS NO: | 632-69-9 |
包装: | 50mg |
市场价: | 305元 |
Cas No. | 632-69-9 |
别名 | 酸性红 94 |
化学名 | sodium 2,3,4,5-tetrachloro-6-(2,4,5,7-tetraiodo-6-oxido-3-oxo-3H-xanthen-9-yl)benzoate |
Canonical SMILES | IC1=C(C(C(C(C(C([O-])=O)=C2Cl)=C(C(Cl)=C2Cl)Cl)=C3C=C4I)=CC(I)=C1[O-])OC3=C(C4=O)I.[Na+].[Na+] |
分子式 | C20H2Cl4I4Na2O5 |
分子量 | 1017.64 |
溶解度 | <101.76mg/ml in Water;<50.88mg/ml in DMSO |
储存条件 | Store at RT, protect from light, stored under nitrogen |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | Ki: 19 and 64 nM for VGlut andVMAT, respectively Rose Bengal is a potent VGlut and vesicular monoamine transporter (VMAT) inhibitor. The common biochemical l-glutamate (Glu) is widely recognized as the major excitatory neurotransmitter in the vertebrate CNS. Proper Glu transmission plays a critical role in physiological brain functions, such as learning and memory formation as well as basic neural communication. In vitro: Rose Bengal was a quite potent membrane-permeant inhibitor of glutamate uptake into isolated synaptic vesicles. Such vesicular Glu uptake inhibition was achieved without affecting H1-pump ATPase. It was found that various degrees of reduction elicited by Rose Bengal in [3H]Glu in synaptic vesicles inside the synaptosome [1]. In vivo: The distribution of i.v. administered rose bengal was found to depend on its dose. At a low dose, rose bengal could be found almost solely in the liver and plasma. However, at higher doses, the amount of rose bengal found in extra-hepatic tissues gradually increased. The hepatic transfer maximum of rose bengal amounted to 146 micrograms/kg/min. By increasing the dose from 10 to 200 mg/kg, the hepatic concentration of rose bengal also approached a maximum. The storage capacity of the liver, however, did not limit the transfer maximum of rose bengal [1]. Clinical trial: N/A References: |